Agios Pharmaceuticals, INC Form 4 insider transactions

Director Jacqualyn Fouse of Agios Pharmaceuticals reports acquisition of shares through restricted stock unit vesting and subsequent sale to cover tax obligations.

Director Kaye Foster-Cheek reported a transaction involving Agios Pharmaceuticals stock on March 7, 2024.

Director Kaye I. Foster-Cheek of Agios Pharmaceuticals sold shares of common stock in multiple transactions on March 5th and 6th, 2024.

Theodore James Jr. Washburn, Principal Accounting Officer of Agios Pharmaceuticals, sold 1,913 shares of common stock at $31.75 per share on March 5, 2024.

Sarah Gheuens, Chief Medical Officer of Agios Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options, in recent transactions.

Cecilia Jones, CFO of Agios Pharmaceuticals, reports acquisition and disposal of company stock and derivative securities, including stock options and restricted stock units.

Theodore James Jr. Washburn, Principal Accounting Officer of Agios Pharmaceuticals, reports acquisition and disposal of common stock and restricted stock units.

CEO Brian Goff of Agios Pharmaceuticals reports acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options.

James William Burns, Chief Legal Officer of Agios Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options, in recent transactions.

Tsveta Milanova, Chief Commercial Officer of Agios Pharmaceuticals, recently acquired stock options and restricted stock units, signaling potential future ownership in the company.

Director David Schenkein exercised stock options and sold shares of Agios Pharmaceuticals on February 27, 2024.

Director David Schenkein exercised stock options and sold shares of Agios Pharmaceuticals in multiple transactions on February 23 and 26, 2024.